CellGate Inc.

Scientists at CellGate Inc. say they have demonstrated that linking short peptide polymers of the amino acid arginine to a drug molecule will both increase the molecule's water solubility and help get it through the cell membrane. Moreover, this proprietary strategy for enhancing drug bioavailability appears to work with any class of compound. Harnessing this universal transporter technology, CellGate plans to build a service business around taking well-characterized molecules and turning them into better drugs.

Scientists at CellGate Inc. say they have demonstrated that linking short peptide polymers of the amino acid arginine to a drug molecule will both increase the molecule's water solubility and help get it through the cell membrane. Moreover, this proprietary strategy for enhancing drug bioavailability appears to work with any class of compound. Harnessing this universal transporter technology, CellGate plans to build a service business around taking well-characterized molecules and turning them into better drugs.

Company scientific founder Jonathan Rothbard left ImmuLogic Pharmaceutical Corp. in late 1994 for Stanford University School of Medicine ...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.